Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: A project of the Kyushu University Liver Diseases Study Group

Norihiro Furusyo; Masaki Katoh; Yuichi Tababe; Eiji Kajiwara; Toshihiro Maruyama; Junya Shimono; Hironori Sakai; Makoto Nakamuta; Hideyuki Nomura; Akihide Masumoto; Shinji Shimoda; Kazuhiro Takahashi; Koichi Azuma; Jun Hayashi; H. Nakashima; M. Murata; K. Toyoda; H. Takeoka; T. Kuga; A. Mitsutake; R. Sugimoto; H. Amagase; S. Tominaga; K. Yanagita; K. Ogiwara; M. Tokumatsu; S. Tabata; M. Yokota; H. Tanaka; S. Nagase; S. Tsuruta; S. Tada; M. Nagano; M. Honda; T. Umeno; T. Sugimura; S. Ueno; K. Miki; H. Okubo; H. Fujimoto; N. Higuchi; S. Shigematsu; N. Higashi

doi:10.3748/wjg.v12.i5.784

Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: A project of the Kyushu University Liver Diseases Study Group

Norihiro Furusyo, Masaki Katoh, Yuichi Tababe, Eiji Kajiwara, Toshihiro Maruyama, Junya Shimono, Hironori Sakai, Makoto Nakamuta, Hideyuki Nomura, Akihide Masumoto, Shinji Shimoda, Kazuhiro Takahashi, Koichi Azuma, Jun Hayashi, H. Nakashima, M. Murata, K. Toyoda, H. Takeoka, T. Kuga, A. MitsutakeR. Sugimoto, H. Amagase, S. Tominaga, K. Yanagita, K. Ogiwara, M. Tokumatsu, S. Tabata, M. Yokota, H. Tanaka, S. Nagase, S. Tsuruta, S. Tada, M. Nagano, M. Honda, T. Umeno, T. Sugimura, S. Ueno, K. Miki, H. Okubo, H. Fujimoto, N. Higuchi, S. Shigematsu, N. Higashi

Internal Medicine

Research output: Contribution to journal › Article

16 Citations (Scopus)

Abstract

Aim: To determine the efficacy of an interferon alpha and ribavirin combination treatment for Japanese patients infected with hepatitis C virus (HCV) of genotype 2, a multi-center study was retrospectively analyzed. Methods: In total, 173 patients with HCV genotype 2 started to receive interferon-alpha subcutaneously thrice a week and 600-800 mg of ribavirin daily for 24 wk. Results: The overall sustained virological response (SVR), defined as undetectable HCV RNA in serum, 24 wk after the end of treatment, was remarkably high by 84.4%, (146/173) by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without the discontinuation of ribavirin (46.9% vs 92.9%), but no difference was found between those with and without a dose reduction of ribavirin. A significant difference in SVR was also found between patients with less than 16 wk and patients with 16 or more weeks of ribavirin treatment (34.8% vs 92.0%). Conclusion: The 24-wk interferon and ribavirin treatment is highly effective for Japanese patients with HCV genotype 2. The significant predictor of SVR is continuation of the ribavirin treatment for up to 16 weeks.

Original language	English
Pages (from-to)	784-790
Number of pages	7
Journal	World Journal of Gastroenterology
Volume	12
Issue number	5
DOIs	https://doi.org/10.3748/wjg.v12.i5.784
Publication status	Published - Feb 7 2006

All Science Journal Classification (ASJC) codes

Gastroenterology

Access to Document

10.3748/wjg.v12.i5.784

Fingerprint Dive into the research topics of 'Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: A project of the Kyushu University Liver Diseases Study Group'. Together they form a unique fingerprint.

Cite this

Furusyo, N., Katoh, M., Tababe, Y., Kajiwara, E., Maruyama, T., Shimono, J., Sakai, H., Nakamuta, M., Nomura, H., Masumoto, A., Shimoda, S., Takahashi, K., Azuma, K., Hayashi, J., Nakashima, H., Murata, M., Toyoda, K., Takeoka, H., Kuga, T., ... Higashi, N. (2006). Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: A project of the Kyushu University Liver Diseases Study Group. World Journal of Gastroenterology, 12(5), 784-790. https://doi.org/10.3748/wjg.v12.i5.784

Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2 : A project of the Kyushu University Liver Diseases Study Group. / Furusyo, Norihiro; Katoh, Masaki; Tababe, Yuichi; Kajiwara, Eiji; Maruyama, Toshihiro; Shimono, Junya; Sakai, Hironori; Nakamuta, Makoto; Nomura, Hideyuki; Masumoto, Akihide; Shimoda, Shinji; Takahashi, Kazuhiro; Azuma, Koichi; Hayashi, Jun; Nakashima, H.; Murata, M.; Toyoda, K.; Takeoka, H.; Kuga, T.; Mitsutake, A.; Sugimoto, R.; Amagase, H.; Tominaga, S.; Yanagita, K.; Ogiwara, K.; Tokumatsu, M.; Tabata, S.; Yokota, M.; Tanaka, H.; Nagase, S.; Tsuruta, S.; Tada, S.; Nagano, M.; Honda, M.; Umeno, T.; Sugimura, T.; Ueno, S.; Miki, K.; Okubo, H.; Fujimoto, H.; Higuchi, N.; Shigematsu, S.; Higashi, N.

In: World Journal of Gastroenterology, Vol. 12, No. 5, 07.02.2006, p. 784-790.

Research output: Contribution to journal › Article

Furusyo, N, Katoh, M, Tababe, Y, Kajiwara, E, Maruyama, T, Shimono, J, Sakai, H, Nakamuta, M, Nomura, H, Masumoto, A, Shimoda, S, Takahashi, K, Azuma, K, Hayashi, J, Nakashima, H, Murata, M , Toyoda, K, Takeoka, H, Kuga, T, Mitsutake, A, Sugimoto, R, Amagase, H, Tominaga, S, Yanagita, K, Ogiwara, K, Tokumatsu, M, Tabata, S, Yokota, M, Tanaka, H, Nagase, S, Tsuruta, S, Tada, S, Nagano, M, Honda, M, Umeno, T, Sugimura, T, Ueno, S, Miki, K, Okubo, H, Fujimoto, H, Higuchi, N, Shigematsu, S & Higashi, N 2006, 'Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: A project of the Kyushu University Liver Diseases Study Group', World Journal of Gastroenterology, vol. 12, no. 5, pp. 784-790. https://doi.org/10.3748/wjg.v12.i5.784

Furusyo, Norihiro ; Katoh, Masaki ; Tababe, Yuichi ; Kajiwara, Eiji ; Maruyama, Toshihiro ; Shimono, Junya ; Sakai, Hironori ; Nakamuta, Makoto ; Nomura, Hideyuki ; Masumoto, Akihide ; Shimoda, Shinji ; Takahashi, Kazuhiro ; Azuma, Koichi ; Hayashi, Jun ; Nakashima, H. ; Murata, M. ; Toyoda, K. ; Takeoka, H. ; Kuga, T. ; Mitsutake, A. ; Sugimoto, R. ; Amagase, H. ; Tominaga, S. ; Yanagita, K. ; Ogiwara, K. ; Tokumatsu, M. ; Tabata, S. ; Yokota, M. ; Tanaka, H. ; Nagase, S. ; Tsuruta, S. ; Tada, S. ; Nagano, M. ; Honda, M. ; Umeno, T. ; Sugimura, T. ; Ueno, S. ; Miki, K. ; Okubo, H. ; Fujimoto, H. ; Higuchi, N. ; Shigematsu, S. ; Higashi, N. / Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2 : A project of the Kyushu University Liver Diseases Study Group. In: World Journal of Gastroenterology. 2006 ; Vol. 12, No. 5. pp. 784-790.

@article{d3b2feb403ec421384125b79e9541203,

title = "Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: A project of the Kyushu University Liver Diseases Study Group",

abstract = "Aim: To determine the efficacy of an interferon alpha and ribavirin combination treatment for Japanese patients infected with hepatitis C virus (HCV) of genotype 2, a multi-center study was retrospectively analyzed. Methods: In total, 173 patients with HCV genotype 2 started to receive interferon-alpha subcutaneously thrice a week and 600-800 mg of ribavirin daily for 24 wk. Results: The overall sustained virological response (SVR), defined as undetectable HCV RNA in serum, 24 wk after the end of treatment, was remarkably high by 84.4%, (146/173) by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without the discontinuation of ribavirin (46.9% vs 92.9%), but no difference was found between those with and without a dose reduction of ribavirin. A significant difference in SVR was also found between patients with less than 16 wk and patients with 16 or more weeks of ribavirin treatment (34.8% vs 92.0%). Conclusion: The 24-wk interferon and ribavirin treatment is highly effective for Japanese patients with HCV genotype 2. The significant predictor of SVR is continuation of the ribavirin treatment for up to 16 weeks.",

author = "Norihiro Furusyo and Masaki Katoh and Yuichi Tababe and Eiji Kajiwara and Toshihiro Maruyama and Junya Shimono and Hironori Sakai and Makoto Nakamuta and Hideyuki Nomura and Akihide Masumoto and Shinji Shimoda and Kazuhiro Takahashi and Koichi Azuma and Jun Hayashi and H. Nakashima and M. Murata and K. Toyoda and H. Takeoka and T. Kuga and A. Mitsutake and R. Sugimoto and H. Amagase and S. Tominaga and K. Yanagita and K. Ogiwara and M. Tokumatsu and S. Tabata and M. Yokota and H. Tanaka and S. Nagase and S. Tsuruta and S. Tada and M. Nagano and M. Honda and T. Umeno and T. Sugimura and S. Ueno and K. Miki and H. Okubo and H. Fujimoto and N. Higuchi and S. Shigematsu and N. Higashi",

year = "2006",

month = feb,

day = "7",

doi = "10.3748/wjg.v12.i5.784",

language = "English",

volume = "12",

pages = "784--790",

journal = "World Journal of Gastroenterology",

issn = "1007-9327",

publisher = "WJG Press",

number = "5",

}

TY - JOUR

T1 - Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2

T2 - A project of the Kyushu University Liver Diseases Study Group

AU - Furusyo, Norihiro

AU - Katoh, Masaki

AU - Tababe, Yuichi

AU - Kajiwara, Eiji

AU - Maruyama, Toshihiro

AU - Shimono, Junya

AU - Sakai, Hironori

AU - Nakamuta, Makoto

AU - Nomura, Hideyuki

AU - Masumoto, Akihide

AU - Shimoda, Shinji

AU - Takahashi, Kazuhiro

AU - Azuma, Koichi

AU - Hayashi, Jun

AU - Nakashima, H.

AU - Murata, M.

AU - Toyoda, K.

AU - Takeoka, H.

AU - Kuga, T.

AU - Mitsutake, A.

AU - Sugimoto, R.

AU - Amagase, H.

AU - Tominaga, S.

AU - Yanagita, K.

AU - Ogiwara, K.

AU - Tokumatsu, M.

AU - Tabata, S.

AU - Yokota, M.

AU - Tanaka, H.

AU - Nagase, S.

AU - Tsuruta, S.

AU - Tada, S.

AU - Nagano, M.

AU - Honda, M.

AU - Umeno, T.

AU - Sugimura, T.

AU - Ueno, S.

AU - Miki, K.

AU - Okubo, H.

AU - Fujimoto, H.

AU - Higuchi, N.

AU - Shigematsu, S.

AU - Higashi, N.

PY - 2006/2/7

Y1 - 2006/2/7

N2 - Aim: To determine the efficacy of an interferon alpha and ribavirin combination treatment for Japanese patients infected with hepatitis C virus (HCV) of genotype 2, a multi-center study was retrospectively analyzed. Methods: In total, 173 patients with HCV genotype 2 started to receive interferon-alpha subcutaneously thrice a week and 600-800 mg of ribavirin daily for 24 wk. Results: The overall sustained virological response (SVR), defined as undetectable HCV RNA in serum, 24 wk after the end of treatment, was remarkably high by 84.4%, (146/173) by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without the discontinuation of ribavirin (46.9% vs 92.9%), but no difference was found between those with and without a dose reduction of ribavirin. A significant difference in SVR was also found between patients with less than 16 wk and patients with 16 or more weeks of ribavirin treatment (34.8% vs 92.0%). Conclusion: The 24-wk interferon and ribavirin treatment is highly effective for Japanese patients with HCV genotype 2. The significant predictor of SVR is continuation of the ribavirin treatment for up to 16 weeks.

AB - Aim: To determine the efficacy of an interferon alpha and ribavirin combination treatment for Japanese patients infected with hepatitis C virus (HCV) of genotype 2, a multi-center study was retrospectively analyzed. Methods: In total, 173 patients with HCV genotype 2 started to receive interferon-alpha subcutaneously thrice a week and 600-800 mg of ribavirin daily for 24 wk. Results: The overall sustained virological response (SVR), defined as undetectable HCV RNA in serum, 24 wk after the end of treatment, was remarkably high by 84.4%, (146/173) by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without the discontinuation of ribavirin (46.9% vs 92.9%), but no difference was found between those with and without a dose reduction of ribavirin. A significant difference in SVR was also found between patients with less than 16 wk and patients with 16 or more weeks of ribavirin treatment (34.8% vs 92.0%). Conclusion: The 24-wk interferon and ribavirin treatment is highly effective for Japanese patients with HCV genotype 2. The significant predictor of SVR is continuation of the ribavirin treatment for up to 16 weeks.

UR - http://www.scopus.com/inward/record.url?scp=33644889900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644889900&partnerID=8YFLogxK

U2 - 10.3748/wjg.v12.i5.784

DO - 10.3748/wjg.v12.i5.784

M3 - Article

C2 - 16521196

AN - SCOPUS:33644889900

VL - 12

SP - 784

EP - 790

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 5

ER -